Bacteroides polymorpha ZF-8 and application thereof in preparation of medicine and food for treating and / or preventing inflammatory bowel disease

Abstract

The invention belongs to the technical field of intestinal microorganisms, and particularly relates to bacteroides polydeformation ZF-8 and application thereof in preparation of drugs and food for treating and / or preventing inflammatory bowel diseases. The invention relates to a bacterial strain, in particular to a bacterial strain ZF-8, and the bacterial strain ZF-8 is a bacterial strain ZF-8. The strain is separated from the intestinal tract of a healthy human body and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 2025618. The bacterial strain can protect colorectal mucosa from being damaged and repair the damaged intestinal mucosa, so that symptoms such as loose stool, hematochezia and colorectal shortening are improved, weight loss caused by intestinal injury and inflammation is relieved, and finally, the inflammatory bowel disease is treated.

Description

Technical Field

[0001] The present invention belongs to the technical field of intestinal microorganisms, and in particular relates to a strain of Bacteroides polymorpha ZF-8 and its use in preparing medicines and foods for treating and / or preventing inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD) clinically encompasses ulcerative colitis (UC) and Crohn's disease (CD) (PMID: 39261229). The pathogenesis of IBD is complex and remains unclear, but it is associated with multiple factors, including genetics, environment, diet, and lifestyle (PMID: 29018271). Recent studies have revealed that the gut microbiome plays a crucial role in the development and progression of IBD (PMID: 40065181). Dysbiosis can lead to a decrease in beneficial bacteria and an increase in harmful bacteria, which in turn damages the intestinal mucosal barrier and triggers abnormal inflammatory responses in the intestinal tissue (PMID: 32913180; PMID: 37734419). Therefore, targeting the microbiome to correct this imbalance is considered a potential therapeutic strategy for IBD.

[0003] Bacteroides ( Bacteroides spp.) are important commensal bacteria in the human intestine and are crucial for immune regulation and metabolic health (PMID: 39926224). Bacteroides bacteria are widely considered to be the source of next-generation probiotics and have important development value (PMID: 30716990). Bacteroides multiformis ) is a new species of Bacteroides, an obligate anaerobic bacterium with a spherical, ovoid, or rod-shaped shape (PMID: 36192813). In 2021, ChangLiu et al. first isolated Bacteroides multiproteus (PMID: 36192813) from a fecal sample of a healthy adult. As a new species of Bacteroides, Bacteroides multiproteus has significant potential for development. However, its pharmacological effects remain largely unknown.

[0004] Using systematic culturomics techniques, the research team isolated a strain of Bacteroides multiproteus ZF-8 from healthy human fecal samples. This strain demonstrated significant anti-inflammatory and intestinal protective effects in experimental studies. Existing research on the application of Bacteroides multiproteus ZF-8 in the treatment of inflammatory bowel disease is lacking, and current treatments still suffer from limited efficacy and numerous side effects. Therefore, this bacterium shows broad application prospects in the preparation of drugs and foods for the treatment and / or prevention of inflammatory bowel disease. Summary of the Invention

[0005] Based on the deficiencies in existing treatments for inflammatory bowel disease (IBD), particularly the lack of a technical solution for achieving efficient treatment through intestinal microbial regulation, the present invention aims to provide a strain of Bacteroides multiproteus ZF-8 and its use in the preparation of drugs and foods for the treatment and / or prevention of inflammatory bowel disease.

[0006] First, the present invention provides a novel strain of Bacteroides polymorpha, which is Bacteroides polymorpha ZF-8, deposited in China Center for Type Culture Collection, with a deposit number of CCTCC NO: M 2025618, a deposit date of March 28, 2025, and is classified as Bacteroides polymorpha. Bacteroides multiformis, The deposit address is China Center for Type Culture Collection, No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, China.

[0007] Secondly, the present invention provides the use of Bacteroides multiproteus ZF-8 in the preparation of a medicament for treating and / or preventing inflammatory bowel disease.

[0008] Furthermore, the inflammatory bowel disease is induced by dextran sulfate sodium.

[0009] Furthermore, the present invention provides a drug for treating and / or preventing inflammatory bowel disease, comprising an effective amount of Bacteroides polymorpha ZF-8.

[0010] Furthermore, the dosage form of the drug is a liquid preparation or a solid preparation, and the concentration of live bacteria of Bacteroides polymorpha ZF-8 in the drug is (1-9)×10 9 CFU / mL, the dosage of the drug is (1~9)×10 9 CFU / kg / day to (1~9)×10 11 CFU / kg / day.

[0011] Preferably, the optimal dosage of the drug is (1-9)×10 10 CFU / kg / day, administered by oral gavage.

[0012] In addition, the present invention also provides the use of the Bacteroides polymorpha ZF-8 in preparing food for alleviating weight loss.

[0013] Furthermore, the weight loss is caused by intestinal inflammation, intestinal damage, loose stools, bloody stools, etc.

[0014] Compared with the prior art, the present invention has the following beneficial effects: First, a novel strain of Bacteroides polymorpha ZF-8 was provided, which has significant anti-inflammatory and intestinal protective effects. Second, the application of Bacteroides polymorpha ZF-8 in the treatment of inflammatory bowel disease was clarified, especially its significant effect in relieving symptoms such as loose stools, bloody stools, weight loss, and colorectal shortening. Third, a medium dose (1.6×10¹ 0 CFU / kg / day) is the optimal therapeutic dose, providing an important reference for subsequent drug development; finally, this strain is not only suitable for drug development, but can also be used to prepare functional foods, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The figure is a comparison of the disease activity index (DAI) of mice in each group; Among them, the NC group was the natural growth control group; The MD group was a dextran sulfate sodium (DSS)-fed disease model group; The BM-L group was treated with low-dose Bacteroides multiforme ZF-8 by oral gavage; The BM-M group was treated with medium-dose Bacteroides multiforme ZF-8 by oral gavage; The BM-H group was treated with high-dose Bacteroides multiforme ZF-8 by oral gavage; Total: total score; Stool consistency: stool consistency score; Occult / gross bleeding: occult or gross bleeding score; Body weight: weight score; *Indicates significant difference compared with the NC group (P < 0.05); ** indicates a very significant difference compared with the NC group (P<0.01); # indicates significant difference compared with the MD group (P < 0.05); ## indicates extremely significant difference compared with the MD group (P<0.01); Scoring was performed according to the method in the literature (PMID: 34973740), and statistical tests were performed using Student t-test. The data were presented as mean ± standard error (SEM).

[0016] Figure 2 is the graph of the weight change rate of mice; Among them, * indicates significant difference compared with the NC group (P < 0.05); ** indicates a very significant difference compared with the NC group (P<0.01); # indicates significant difference compared with the MD group (P < 0.05); ## indicates extremely significant difference compared with the MD group (P<0.01); Student's t-test was used for statistical analysis, and the data were presented as mean ± standard error of the mean (SEM).

[0017] Figure 3 The figure is a comparison of the colorectal length of mice in each group; Among them, * indicates significant difference compared with the NC group (P < 0.05); ** indicates a very significant difference compared with the NC group (P<0.01); # indicates significant difference compared with the MD group (P < 0.05); ## indicates a very significant difference compared with the MD group (P<0.01). Statistical tests were performed using Student's t-test, and data were presented as mean ± standard error of the mean (SEM).

[0018] Figure 4 The following is a comparison of the colorectal tissue morphology of mice in each group. The colorectal tissues of 5 mice in each group were selected for display.

[0019] Figure 5 Figure 2 shows the hematoxylin-eosin (HE) staining of the colorectum of mice in each group. Bar = 100 μm. HE staining of colorectal tissues of 5 mice in each group was used for display.

[0020] Figure 6 Figure 2 is the colorectal tissue damage score of mice in each group. Among them, * indicates significant difference compared with the NC group (P < 0.05); ** indicates a very significant difference compared with the NC group (P<0.01); # indicates significant difference compared with the MD group (P < 0.05); ## indicates a very significant difference compared with the MD group (P<0.01). Scoring was performed according to the method in the literature (PMID: 34973740), and statistical tests were performed using Student t-test. Data are presented as mean ± standard error (SEM). DETAILED DESCRIPTION

[0021] In a specific embodiment, a novel strain of Bacteroides polymorpha ZF-8 and its use in the preparation of a medicament for treating and / or preventing inflammatory bowel disease is provided. The inflammatory bowel disease is induced by dextran sodium sulfate, and the inflammatory bowel disease also includes inflammatory bowel disease induced by other factors.

[0022] In a specific embodiment, a drug for treating and / or preventing inflammatory bowel disease is provided, comprising Bacteroides polymorpha ZF-8. The drug is preferably in the form of a liquid preparation or a solid preparation, more preferably a liquid preparation.

[0023] When the dosage form of the drug is a solid bacterial preparation, the drug is prepared by freeze-drying a bacterial solution of Bacteroides polymorpha ZF-8. The concentration of live bacteria of Bacteroides polymorpha ZF-8 in the drug is preferably (1-9)×10 9 CFU / mL. The solvent of the drug is preferably phosphate buffered saline (PBS), the drug is preferably administered orally, and the dosage of the drug is preferably (1-9)×10 9 CFU / kg / day to (1~9)×10 11 CFU / kg / day, further, preferably (1~9)×10 10 CFU / kg / day.

[0024] Specific embodiments also provide the use of the Bacteroides polyproteus ZF-8 in preparing food. The dosage form of the food is not particularly limited and can be any conventional food dosage form in the art, such as a solid or liquid preparation. When the food is a solid bacterial preparation, the food is prepared by freeze-drying a bacterial solution of Bacteroides polyproteus ZF-8. In the present invention, the food also includes food-acceptable excipients, the type and amount of which are not particularly limited.

[0025] The following describes embodiments of the present application in more detail with reference to the accompanying drawings. Although the accompanying drawings illustrate embodiments of the present application, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments described herein. Rather, these embodiments are provided to make the present application more thorough and complete, and to fully convey the scope of the present application to those skilled in the art.

[0026] In order to make the purpose, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially. Based on the embodiments in the present application, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of this application.

[0027] Example 1

[0028] In this embodiment, the culture process of Bacteroides polymorpha ZF-8 includes the following steps: (1) Preparation of culture medium Prepare BHI liquid culture medium with the following ingredients: 10 g / L peptone, 12.5 g / L dehydrated calf brain extract powder, 5 g / L dehydrated ox heart extract powder, 5 g / L sodium chloride, 2 g / L glucose, and 2.5 g / L disodium hydrogen phosphate. The solvent is distilled water with a pH of 7.4 ± 0.2. Pour the culture medium into anaerobic vials, fill with nitrogen, seal, and sterilize with high-pressure steam at 121°C for 15 min.

[0029] (2) Pretreatment of feces Fresh feces from a volunteer was taken and prepared into a 20% (wt / vol) suspension with phosphate buffered saline (PBS) at a pH of 7.0. The suspension was thoroughly mixed and then filtered through a metal sieve with a diameter of 2 mm to remove large food particles to obtain a fecal PBS solution.

[0030] (3) Inoculation and culture The resulting fecal PBS solution was inoculated into autoclaved anaerobic vials and enriched at 37°C for 24 hours. After 24 hours, a 10-fold dilution was applied to plates with a 100 μL coating volume on BHI solid medium. The plates were incubated at 37°C in an anaerobic workstation for 24 hours. Single colonies were then picked and transferred to anaerobic vials of liquid medium for subculture and purification.

[0031] (4) Identification of strains a. Referring to the research methods in the previous literature (PMID: 36192813), the physiological and biochemical characteristics of strain ZF-8 were identified as shown in Table 1.

[0032] Table 1 Biochemical characteristics of strain ZF-8 (where - indicates negative and + indicates positive) English Chinese Identification results D-fructose D-fructose + D-cellobiose D-cellobiose + L-fucose L-fucose + D-mannose D-mannose + D-galactose D-Galactose + Lactulose Lactulose + L-rhamnose L-Rhamnose + b.16S rDNA sequence analysis DNA extraction: DNA was extracted from the strain ZF-8 obtained in step (3) using a stool analysis kit (Cat No. 6547050) from MP Biomedicals, USA.

[0033] 16S rDNA full-length amplification: Primer sequences: 27f: 5'-CAGAGTTTGATCCTGGCT-3', SEQ ID NO.2 1492r: 5'-AGGAGGTGATCCAGCCGCA-3', SEQ ID No.3 Amplification system: 25 μL reaction system, 100 ng DNA template, 2.5 μL 10× PCR Buffer, 0.5 μL dNTP Mix (10 mM), 0.5 μL each of 10 μM upstream and downstream primers, 0.2 μL Taq enzyme (5 U / μL), and add deionized water to make up to 25 μL.

[0034] Amplification conditions: pre-denaturation at 94°C for 5 min, cycling at 94°C for 35 s, 55°C for 35 s, and 72°C for 1 min for 35 cycles, and extension for 8 min.

[0035] The PCR product was purified and sent to Sangon Biotech Co., Ltd. (Shanghai, China) for DNA sequencing (as shown in SEQ ID No. 1). The sequencing results were submitted to the NCBI database for Blast comparison. The comparison results showed that the strain was Bacteroides multiformis The homology was 99.71%. The sequencing results were submitted to the EzBioCloud website for comparison. The comparison results showed that the strain was Bacteroides multiformis The homology was 99.90%. Based on the physiological and biochemical characteristics and the 16S rDNA sequence comparison results of the two websites, we identified strain ZF-8 as Bacteroides polymorpha ( Bacteroides multiformis ), named Bacteroides polymorpha ZF-8.

[0036] SEQ ID No.1 sequence is: Example 2

[0037] This example is the use of Bacteroides polymorpha ZF-8 in the treatment of inflammatory bowel disease 1. Experimental Materials: 50 C57BL / 6J mice (7-week-old, male) were purchased from Weitonglihua Laboratory Animal Technology Co., Ltd. (Beijing) (Certificate No. SCXK (Beijing) 2016-0011); dextran sulfate sodium (DSS, Cat No. 160110) was purchased from MP Biomedicals, USA.

[0038] The main experimental equipment: anaerobic workstation (AW500SG) from Electrotek, UK, and Olympus microscope (CKX41SF).

[0039] Experimental strain culture method: Bacteroides polymorpha ZF-8 obtained in Example 1 was inoculated into a 20 mL anaerobic vial containing high-temperature sterilized BHI liquid medium at a 1% (v / v) inoculum. The anaerobic gas composition in the anaerobic vial was 80% (v / v) N2, 10% (v / v) H2, and 10% (v / v) CO2. The resulting bacterial liquid was incubated at 37°C for 24 hours to obtain a seed solution. The seed solution was then inoculated into a large anaerobic vial (100 mL) containing the above-mentioned high-temperature sterilized medium at a 5% (v / v) inoculum for fermentation at 37°C. After 24 hours of fermentation, the bacteria were collected by centrifugation.

[0040] 2. Experimental methods: (1) Experimental animal grouping and model establishment Fifty male C57BL / 6 mice (seven weeks old, weighing approximately 20 g) were randomly divided into five groups: normal control (NC, n=10), model control (MD, n=10), low-dose Bacteroides multiforme ZF-8 (BM-L, n=10), medium-dose Bacteroides multiforme ZF-8 (BM-M, n=10), and high-dose Bacteroides multiforme ZF-8 (BM-H, n=10). All mice were housed at approximately 23°C with a 12-h light-dark cycle and ad libitum access to standard chow and water. After a one-week acclimation period, the mice were treated with the drug and then induced.

[0041] During the experiment, Mice in the NC group drank water normally and were gavaged with 150 μL of PBS daily for 6 consecutive days; The drinking water of mice in the MD group was supplemented with 2.2% (wt / vol) DSS solution, which was replaced with normal drinking water on the 6th day, and 150 μL of PBS was gavage-fed daily for 6 consecutive days; The drinking water of the mice in the drug group was supplemented with 2.2% (wt / vol) DSS solution, which was replaced with normal drinking water on the 6th day. 9 CFU / kg / day, 1.6×10 10 CFU / kg / day and 1.6×10 11 The mice were gavaged with Bacteroides polymorpha ZF-8 suspension at a dose of 100 CFU / kg / day for 6 consecutive days.

[0042] The volume of bacterial solution administered to each mouse per day was 150 μL, and the bacterial solution of Bacteroides polymorpha ZF-8 was composed of a concentration of 4×10 9 The original fermentation bacterial solution with CFU / mL was centrifuged and resuspended in PBS.

[0043] On day 7, all mice were sacrificed and colorectal tissues were collected for further experiments. The model was successfully established if the MD group exhibited more pronounced symptoms than the NC group, including weight loss, bloody stools, loose stools, and shortened colorectum, and if the pathological score of intestinal sections was significantly higher than that of the NC group.

[0044] (2) Histopathological examination After mice were sacrificed, the posterior 0.5 cm of the colorectum was removed and fixed in 4% paraformaldehyde. The sections were then washed with anhydrous ethanol before embedding in paraffin. Sections were cut into 5 μm sections and stained with hematoxylin and eosin to examine colorectal mucosal damage. The sections were observed under a microscope (Olympus CKX41SF) and photographed.

[0045] 3. Experimental results and analysis In step 1, based on the weight changes of mice in step 2, as well as daily observations of stool consistency and blood in stool, the disease activity index (DAI) of mice was determined according to the literature method and an image was plotted (PMID: 36986080).

[0046] The results are as follows Figure 1 As shown in Table 2, the DAI values ​​of mice in the NC group remained around 0-1, with little weight loss, normal stool hardness, and no loose or bloody stools. Compared with the NC group, mice in the MD group had significantly increased DAI scores, a significant weight loss, severe loose and bloody stools, and extremely significant differences in DAI scores for various disease indicators compared with those in the NC group. Compared with the MD group, mice in the BM-L, BM-M, and BM-H groups experienced a more gradual weight loss, and their loose and bloody stools were significantly improved. The DAI scores of mice in the BM-L, BM-M, and BM-H groups were significantly lower than those in the MD group, with significant or extremely significant differences. These results further demonstrate that Bacteroides polymorpha ZF-8 can alleviate DSS-induced inflammatory bowel disease and improve enteritis symptoms.

[0047] Table 2 Disease activity index (DAI) of mice in each group

[0048] Step 2: Weigh the mice daily and calculate the weight change chart. The results are as follows: Figure 2 and as shown in Table 3.

[0049] Table 3 Body weight changes of mice Group Weight change rate (%) Significance (day 5) Significance (day 6) Significance (day 7) NC 4.84±0.74 - - - MD -13.82±1.47 ** ** ** BM-L -9.25±1.02 **- **- **# BM-M -6.93±1.82 **## **# **## BM-H -8.78±1.54 **- **- **# Figure 2 The results in Table 3 show that the weight of mice in the NC group remained relatively stable during the experiment, while the weight of mice in the MD group increased slightly during the first four days of 2.2% (wt / vol) DSS induction. After the fifth day, the weight of mice in all DSS-induced groups showed a significant downward trend, accompanied by soft, loose stools, and even bloody stools. Weight continued to decrease after cessation of DSS induction, reaching a minimum decrease of approximately 13.82%. Significant differences were observed in the weight change ratios between the NC and MD groups. Compared with the MD group, the weight loss of mice in the BM-L, BM-M, and BM-H groups was slower, with the slowest weight loss in the BM-M group. Furthermore, loose stools and bloody stools were significantly improved. Compared with the MD group, the weight changes of mice in the BM-M group showed extremely significant differences on the 5th and 7th days (P<0.01), and significant differences on the 6th day; there were significant differences between the BM-L and BM-H groups on the 7th day (P<0.05), indicating that the weight of mice in the three treatment groups was significantly restored, among which the mice in the BM-M group were closest to the growth status of normal mice.

[0050] Step 3: After dissecting the mouse, the entire cecum and colorectum were taken, their lengths were measured, and images were drawn. The results are as follows: Figure 3 and as shown in Table 4.

[0051] Figure 3 The results in Table 4 show that compared with the NC group, the colorectal length of mice in the MD group was significantly reduced (P < 0.01). Compared with the MD group, the colorectal length of mice in the BM-M and BM-H groups was significantly increased. Furthermore, the colorectal lengths of the BM-M and BM-H groups were significantly different from those of the MD group (P < 0.05), indicating that colorectal shortening and damage in the BM-M and BM-H groups were significantly improved.

[0052] Table 4 Colorectal length of mice in each group Group Colorectal length (cm) Significance NC 8.46±0.14 MD 5.94±0.22 ** BM-L 6.53±0.21 ** BM-M 6.61±0.14 **# BM-H 6.65±0.21 **# Step 4: After the measurement in step 3, the entire cecum and colorectum of the representative mice in each group were photographed and combined.

[0053] Figure 4 Figure 4 is the colorectal morphology of mice in each group. It can be seen that the colorectum of mice in the MD group was significantly shortened and congested, while the cecum size, morphology and colorectal congestion of mice in the BM-L, BM-M and BM-H groups were significantly better than those in the MD group. In addition, the colorectal length of mice in the BM-M and BM-H groups was significantly increased, which is consistent with the statistical results of colorectal length in Table 4.

[0054] In step 5, approximately 0.5 cm of distal colorectal tissue was collected from each group of mice and fixed in 4% (wt / vol) paraformaldehyde. The fixed tissue was washed with anhydrous ethanol, embedded in paraffin, and sectioned (5 μm). The sections were stained with hematoxylin and eosin (HE) and examined under a microscope, where images were captured.

[0055] like Figure 5 As shown, mice in the NC group had intact intestinal epithelial structure, with clear crypts, prominent and intact goblet cells, and no inflammatory cell infiltration or intestinal mucosal damage. Mice in the MD group developed more pronounced colorectal inflammation and intestinal mucosal damage due to the toxic effects of DSS. Compared with the NC group, mice in the MD group showed loss of intestinal epithelial cell integrity, with significant inflammatory cell infiltration, loss of goblet cells, and crypt damage. Compared with the MD group, mice in the BM-L, BM-M, and BM-H groups showed significantly improved inflammatory cell infiltration and intestinal mucosal damage, with more intact intestinal epithelial cell morphology, prominent goblet cells, and crypt formation. The BM-M group showed the best therapeutic effect. These results further confirm that Bacteroides polymorpha ZF-8 can alleviate and treat DSS-induced inflammatory bowel disease.

[0056] Step 6: Calculate the mouse colorectal tissue damage score based on the HE staining results of step 5 and draw an image.

[0057] like Figure 6 As shown in Table 5, the colorectal tissue damage score was the lowest in the NC group, indicating that the colorectal tissue morphology was good and there was no damage. Compared with the NC group, the colorectal tissue damage score was significantly increased in the MD group, indicating severe colorectal tissue damage. Compared with the MD group, the colorectal tissue damage scores were significantly reduced in the BM-L, BM-M, and BM-H groups, indicating that oral administration of Bacillus multiforme ZF-8 can protect the intestinal mucosa and reduce colorectal tissue damage in mice. The colorectal tissue damage scores of the BM-L and BM-H groups were significantly different from those of the MD group (P < 0.05). The colorectal tissue damage score of the BM-M group was extremely significantly different from that of the MD group (P < 0.01), indicating that the BM-M group had the least colorectal tissue damage and the best treatment effect.

[0058] Table 5 Colorectal tissue damage scores of mice in each group Group Colorectal tissue damage score Significance NC 0 - MD 3.5±0.17 ** BM-L 2.4±0.40 **# BM-M 1.6±0.37 **## BM-H 2.8±0.25 **# Based on the above experimental results, the present invention clarifies the practical application value of Bacteroides multiforme ZF-8 in the treatment of inflammatory bowel disease. This strain can protect the colorectal mucosa from damage and repair the damaged intestinal mucosa, thereby improving symptoms such as loose stools, bloody stools and colorectal shortening, alleviating weight loss caused by intestinal damage and inflammation, and ultimately achieving the treatment of inflammatory bowel disease.

[0059] Based on the research results of this example, Bacteroides polymorpha ZF-8 can be applied to drugs for treating and / or preventing inflammatory bowel disease: The live bacteria of Bacteroides polymorpha ZF-8 are prepared into a preparation for testing. The dosage form of the drug is a solid bacterial preparation. The preparation process is a conventional freeze-drying technology, and the bacterial liquid of Bacteroides polymorpha ZF-8 is freeze-dried and prepared. The live bacteria concentration of Bacteroides polymorpha ZF-8 is preferably (1-9)×10 9 CFU / mL. Phosphate buffered saline (PBS) was selected as the preparation solvent.

[0060] The solid preparation is preferably administered orally. Combined with the DAI scores, weight change rate, colorectal length, colorectal morphology, colorectal HE staining and score comprehensive analysis of the mice in the above groups, the BM-M group showed better therapeutic effects than the BM-L and BM-H groups. Therefore, the preferred dosage of the drug is (1-9)×10 10 Acceptable excipients can be used in the preparation of pharmaceutical preparations, and the drug can also be used in combination with other drugs for the treatment of enteritis.

[0061] According to the research results of this example, Bacteroides polymorpha ZF-8 can be used to prepare foods that alleviate weight loss: The food is a solid bacterial agent, which is prepared by freeze-drying the bacterial liquid of Bacteroides polymorpha ZF-8. During the preparation of the food, acceptable auxiliary materials and additives are used, and there is no special limitation on the types and amounts of the auxiliary materials and additives.

Claims

1. A strain of Bacteroides polymorpha ( Bacteroides multiformis ) ZF-8, characterized in that It is deposited in China Center for Type Culture Collection with the deposit number CCTCC NO: M 2025618.

2. Use of the Bacteroides polymorpha ZF-8 according to claim 1 in the preparation of a medicament for treating and / or preventing inflammatory bowel disease.

3. The use according to claim 2, characterized in that The inflammatory bowel disease is induced by dextran sulfate sodium.

4. A drug for treating and / or preventing inflammatory bowel disease, characterized in that: The method comprises the Bacteroides polymorpha ZF-8 of claim 1.

5. The drug according to claim 4, characterized in that The dosage form of the drug is a liquid preparation or a solid preparation, and the concentration of live bacteria of Bacteroides polymorpha ZF-8 in the drug is (1-9)×10 9 CFU / mL, the dosage of the drug is (1~9)×10 9 CFU / kg / day to (1~9)×10 11 CFU / kg / day.

6. The drug according to claim 5, characterized in that The drug dosage was 1.6×10 10 CFU / kg / day, administered by oral gavage.

7. Use of the Bacteroides polymorpha ZF-8 according to claim 1 in preparing food for alleviating weight loss.

8. The use according to claim 7, characterized in that Causes of weight loss include intestinal inflammation, intestinal damage, loose stools, and blood in the stool.

Images